These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

90 related items for PubMed ID: 11410483

  • 1. Therapy of disseminated B-cell lymphoma xenografts in severe combined immunodeficient mice with an anti-CD74 antibody conjugated with (111)indium, (67)gallium, or (90)yttrium.
    Ochakovskaya R, Osorio L, Goldenberg DM, Mattes MJ.
    Clin Cancer Res; 2001 Jun; 7(6):1505-10. PubMed ID: 11410483
    [Abstract] [Full Text] [Related]

  • 2. Therapy of small subcutaneous B-lymphoma xenografts with antibodies conjugated to radionuclides emitting low-energy electrons.
    Michel RB, Rosario AV, Andrews PM, Goldenberg DM, Mattes MJ.
    Clin Cancer Res; 2005 Jan 15; 11(2 Pt 1):777-86. PubMed ID: 15701868
    [Abstract] [Full Text] [Related]

  • 3. Radionuclides linked to a CD74 antibody as therapeutic agents for B-cell lymphoma: comparison of Auger electron emitters with beta-particle emitters.
    Govindan SV, Goldenberg DM, Elsamra SE, Griffiths GL, Ong GL, Brechbiel MW, Burton J, Sgouros G, Mattes MJ.
    J Nucl Med; 2000 Dec 15; 41(12):2089-97. PubMed ID: 11138697
    [Abstract] [Full Text] [Related]

  • 4. 177Lu-antibody conjugates for single-cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivo.
    Michel RB, Andrews PM, Rosario AV, Goldenberg DM, Mattes MJ.
    Nucl Med Biol; 2005 Apr 15; 32(3):269-78. PubMed ID: 15820762
    [Abstract] [Full Text] [Related]

  • 5. A comparison of 4 radionuclides conjugated to antibodies for single-cell kill.
    Michel RB, Brechbiel MW, Mattes MJ.
    J Nucl Med; 2003 Apr 15; 44(4):632-40. PubMed ID: 12679410
    [Abstract] [Full Text] [Related]

  • 6. Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate.
    Griffiths GL, Mattes MJ, Stein R, Govindan SV, Horak ID, Hansen HJ, Goldenberg DM.
    Clin Cancer Res; 2003 Dec 15; 9(17):6567-71. PubMed ID: 14695162
    [Abstract] [Full Text] [Related]

  • 7. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.
    Sharkey RM, Karacay H, Johnson CR, Litwin S, Rossi EA, McBride WJ, Chang CH, Goldenberg DM.
    J Nucl Med; 2009 Mar 15; 50(3):444-53. PubMed ID: 19223402
    [Abstract] [Full Text] [Related]

  • 8. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys.
    Sapra P, Stein R, Pickett J, Qu Z, Govindan SV, Cardillo TM, Hansen HJ, Horak ID, Griffiths GL, Goldenberg DM.
    Clin Cancer Res; 2005 Jul 15; 11(14):5257-64. PubMed ID: 16033844
    [Abstract] [Full Text] [Related]

  • 9. Antibody localization to B-cell lymphoma xenografts in immunodeficient mice: importance of using residualizing radiolabels.
    Michel RB, Ochakovskaya R, Mattes MJ.
    Clin Cancer Res; 2002 Aug 15; 8(8):2632-9. PubMed ID: 12171895
    [Abstract] [Full Text] [Related]

  • 10. Single-cell cytotoxicity with radiolabeled antibodies.
    Ong GL, Elsamra SE, Goldenberg DM, Mattes MJ.
    Clin Cancer Res; 2001 Jan 15; 7(1):192-201. PubMed ID: 11205908
    [Abstract] [Full Text] [Related]

  • 11. Anti-CD45 and anti-CD52 (Campath) monoclonal antibodies effectively eliminate systematically disseminated human non-Hodgkin's lymphoma B cells in Scid mice.
    de Kroon JF, de Paus RA, Kluin-Nelemans HC, Kluin PM, van Bergen CA, Munro AJ, Hale G, Willemze R, Falkenburg JH.
    Exp Hematol; 1996 Jul 15; 24(8):919-26. PubMed ID: 8690051
    [Abstract] [Full Text] [Related]

  • 12. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
    Shah SA, Halloran PM, Ferris CA, Levine BA, Bourret LA, Goldmacher VS, Blättler WA.
    Cancer Res; 1993 Mar 15; 53(6):1360-7. PubMed ID: 7680284
    [Abstract] [Full Text] [Related]

  • 13. In vitro toxicity of A-431 carcinoma cells with antibodies to epidermal growth factor receptor and epithelial glycoprotein-1 conjugated to radionuclides emitting low-energy electrons.
    Michel RB, Castillo ME, Andrews PM, Mattes MJ.
    Clin Cancer Res; 2004 Sep 01; 10(17):5957-66. PubMed ID: 15355929
    [Abstract] [Full Text] [Related]

  • 14. Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab).
    Mattes MJ, Sharkey RM, Karacay H, Czuczman MS, Goldenberg DM.
    Clin Cancer Res; 2008 Oct 01; 14(19):6154-60. PubMed ID: 18829494
    [Abstract] [Full Text] [Related]

  • 15. Development of a severe combined immunodeficiency (SCID) mouse model consisting of highly disseminated human B-cell leukemia/lymphoma, cure of the tumors by systemic administration of immunotoxin, and development/application of a clonotype-specific polymerase chain reaction-based assay.
    Yoshida M, Rybak RJ, Choi Y, Greenberg SJ, Barcos M, Kawata A, Matsuno F, Tsai H, Seon BK.
    Cancer Res; 1997 Feb 15; 57(4):678-85. PubMed ID: 9044845
    [Abstract] [Full Text] [Related]

  • 16. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters.
    Behr TM, Sgouros G, Stabin MG, Béhé M, Angerstein C, Blumenthal RD, Apostolidis C, Molinet R, Sharkey RM, Koch L, Goldenberg DM, Becker W.
    Clin Cancer Res; 1999 Oct 15; 5(10 Suppl):3031s-3043s. PubMed ID: 10541340
    [Abstract] [Full Text] [Related]

  • 17. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.
    Flavell DJ, Boehm DA, Noss A, Warnes SL, Flavell SU.
    Br J Cancer; 2001 Feb 15; 84(4):571-8. PubMed ID: 11207056
    [Abstract] [Full Text] [Related]

  • 18. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
    Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, Oflazoglu E, Huberman A, Repasky E, Czuczman MS.
    Clin Cancer Res; 2003 Dec 01; 9(16 Pt 1):5866-73. PubMed ID: 14676108
    [Abstract] [Full Text] [Related]

  • 19. Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma.
    DiJoseph JF, Goad ME, Dougher MM, Boghaert ER, Kunz A, Hamann PR, Damle NK.
    Clin Cancer Res; 2004 Dec 15; 10(24):8620-9. PubMed ID: 15623646
    [Abstract] [Full Text] [Related]

  • 20. Localization of an antibody to CD74 (MHC class II invariant chain) to human B cell lymphoma xenografts in nude mice.
    Shih L, Ong GL, Burton J, Mishina D, Goldenberg DM, Mattes MJ.
    Cancer Immunol Immunother; 2000 Jul 15; 49(4-5):208-16. PubMed ID: 10941903
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.